[Treatment strategy for the recurrence of HCV infection after liver transplantation in the era of DAA].

Chronic hepatitis C virus (HCV) infection is a leading cause of end stage liver disease and one of the leading indications for liver transplantation (LT). Recurrence of HCV infection following LT is almost universal and can accelerate graft cirrhosis. However, interferon alfa-based regimens used to treat recurrent HCV infection after LT are poorly tolerated, associated with generally modest efficacy, and can interact with immunosuppressive agents. To improve the efficacy of pre- and post-transplant antiviral therapy, a new class of potent direct-acting antiviral agents (DAAs) has been developed. The aim of this review is to summarize the use of DAAs in LT HCV patients.